Market Intelligence
Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.
Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.
UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.
September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like telmisartan.
After UK apixaban prices started to creep up in July, the latest WaveData figures show several different presentations of the generic increasing their average price by multiples in August.
July’s UK generic pricing figures from WaveData show captopril tablets rocketing up in price, while aripiprazole prices continue to plummet.
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.
The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.
Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.
A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.
Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.
Oxycodone prolonged-release tablets occupied the top five spots in our Biggest Fallers table of the fastest-declining UK generics prices for November. Market researcher WaveData explains.